Tesofensine as a GLP-1 alternative: what the evidence says

What did @dr_jonesdc actually say?

The creator, who identifies as a "holistic obesity expert," pitched tesofensine as a backup option for patients who can't take GLP-1 medications due to contraindications like pancreatitis or a family history of thyroid cancer. They called it "the magic pill" and described it as a "triple monoamine reuptake inhibitor" that boosts serotonin, dopamine, and norepinephrine, leading to faster metabolism and reduced hunger.

The video ends with a sales pitch directing viewers to a free consultation before tesofensine "runs out," which is a classic scarcity tactic. The creator also mentioned using tesofensine alongside "other peptides" without specifying what those are, which is a meaningful omission given the safety implications of stacking compounds.

Does the science back this up?

Partially, but the picture is more complicated than this video lets on. Tesofensine did show impressive weight loss results in early trials, but it has not been approved by the FDA and its development history raises real questions about safety.

The Phase 2 trial the creator references, Astrup et al. (2008, The Lancet), found tesofensine produced significantly greater weight loss than placebo over 24 weeks, with the 1mg dose group losing around 12.8kg on average. That is genuinely notable. However, the same trial flagged increases in heart rate and blood pressure at higher doses, which is not a minor side effect profile. A follow-up analysis by Lund et al. (2017, Obesity Reviews) noted that cardiovascular concerns were a primary reason development stalled after Phase 2. The compound was originally studied for Parkinson's and Alzheimer's disease, not obesity, and it never advanced to Phase 3 trials for weight loss. Calling something that failed to reach Phase 3 a straightforward "alternative" to FDA-approved medications is a stretch.

What did they get wrong (or right)?

Credit where it is due: the mechanism description is broadly accurate. Tesofensine does inhibit the reuptake of serotonin, dopamine, and norepinephrine, and appetite suppression through central mechanisms is well-documented in the literature. The Phase 2 efficacy data is real.

But several claims deserve pushback. Saying tesofensine produces "faster metabolism" is an oversimplification. The weight loss effect appears to be primarily appetite suppression, not a meaningful increase in basal metabolic rate, according to Astrup et al. More importantly, framing tesofensine as a clean "alternative" to GLP-1s glosses over the cardiovascular signal. GLP-1 receptor agonists like semaglutide have cardiovascular outcome trial data supporting their safety, including the SUSTAIN-6 trial (Marso et al., 2016, NEJM). Tesofensine has no equivalent long-term safety data. The creator also never mentions that tesofensine is not FDA-approved, which is a significant omission for a video aimed at patients seeking treatment.

What should you actually know?

Tesofensine is not approved by the FDA for any indication. It is available in the U.S. only through compounding pharmacies operating in a regulatory gray area. That does not automatically make it dangerous, but it does mean patients using it have far less protection than they would with an approved drug.

The cardiovascular concerns from the Lancet trial are not trivial. Patients with hypertension, arrhythmias, or existing cardiovascular disease should be especially cautious. The mention of combining tesofensine with unspecified "other peptides" in this video is concerning from a safety standpoint. Stacking unapproved compounds without specifying what they are or how they interact is not responsible prescribing guidance, and patients should ask direct questions about any combination protocol before agreeing to it.

If you genuinely cannot access GLP-1 medications, there are FDA-approved alternatives worth discussing with a licensed provider, including naltrexone/bupropion (Contrave) and phentermine/topiramate (Qsymia), both of which have more extensive safety data than tesofensine.